Vish Muthusamy, PhD
Research & Publications
Biography
News
Research Summary
I direct the Center for Precision Cancer Modeling (CPCM), which is a research center and core facility sponsored by the Yale Cancer Center to further preclinical development of cancer therapies. My primary research interests include development of therapeutic approaches majorly directed against cancer. I am also interested in development and pharmacological improvement of drugs against other pathological states such as auto-immune and infectious diseases. I have expertise in development of sophisticated in vivo models and utilize these to understand and target the molecular and cellular mechanisms that drive cancer progression. Through the core, I help advance candidate drugs for Yale Investigators from discovery through preclinical stage and set the stage for them to be approved as experimental drugs in clinical trials. Several drugs that I helped develop are currently in various stages of clinical testing.
Coauthors
Selected Publications
- Comprehensive Analysis of Metabolic Isozyme Targets in CancerMarczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research 2022, 82: 1698-1711. PMID: 35247885, PMCID: PMC10883296, DOI: 10.1158/0008-5472.can-21-3983.
- Abstract P5-17-01: Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer modelsFoldi J, Marczyk M, Gunasekharan V, Qing T, Sehgal R, Shan N, Muthusamy V, Umlau S, Surovtseva Y, Kibbey R, Pusztai L. Abstract P5-17-01: Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer models. Cancer Research 2022, 82: p5-17-01-p5-17-01. DOI: 10.1158/1538-7445.sabcs21-p5-17-01.
- Bifunctional small molecules that mediate the degradation of extracellular proteinsCaianiello DF, Zhang M, Ray JD, Howell RA, Swartzel JC, Branham EMJ, Chirkin E, Sabbasani VR, Gong AZ, McDonald DM, Muthusamy V, Spiegel DA. Bifunctional small molecules that mediate the degradation of extracellular proteins. Nature Chemical Biology 2021, 17: 947-953. PMID: 34413525, DOI: 10.1038/s41589-021-00851-1.
- Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responsesJiang X, Muthusamy V, Fedorova O, Kong Y, Kim DJ, Bosenberg M, Pyle AM, Iwasaki A. Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. Journal Of Experimental Medicine 2019, 216: 2854-2868. PMID: 31601678, PMCID: PMC6888973, DOI: 10.1084/jem.20190801.
- Neutralization of Pathogenic Fungi with Small‐Molecule ImmunotherapeuticsChirkin E, Muthusamy V, Mann P, Roemer T, Nantermet PG, Spiegel DA. Neutralization of Pathogenic Fungi with Small‐Molecule Immunotherapeutics. Angewandte Chemie International Edition 2017, 56: 13036-13040. PMID: 28793176, DOI: 10.1002/anie.201707536.
- Neutralization of Pathogenic Fungi with Small‐Molecule ImmunotherapeuticsChirkin E, Muthusamy V, Mann P, Roemer T, Nantermet P, Spiegel D. Neutralization of Pathogenic Fungi with Small‐Molecule Immunotherapeutics. Angewandte Chemie 2017, 129: 13216-13220. DOI: 10.1002/ange.201707536.
- (S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma SurvivalMicevic G, Muthusamy V, Pupo G, Scolyer R, Long G, Bosenberg M. (S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma Survival. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e9. DOI: 10.1016/j.ijrobp.2017.02.065.
- Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase ReceptorRullo A, Fitzgerald K, Muthusamy V, Liu M, Yuan C, Huang M, Kim M, Cho A, Spiegel D. Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie 2016, 128: 3706-3710. DOI: 10.1002/ange.201510866.